ARCA biopharma Announces Second Quarter 2017 Financial Results and Provides Business Update
ARCA BIOPHARMA ANNOUNCES DATABASE LOCK FOR GENETIC-AF PHASE 2B INTERIM EFFICACY ANALYSIS – DSMB RECOMMENDATION ANTICIPATED IN AUGUST 2017
Equities.com Article – “ARCA biopharma (ABIO): Genetically Targeting Cardiovascular Disease”
https://www.equities.com/news/arca-biopharma-abio-genetically-targeting-cardiovascular-disease